On one hand, dysregulation of transcription due to altered histone acetylation patterns is a mechanism for cancer occurrence, which is currently targeted by HDAC inhibitors; on the other hand, the traditional treatment for ovarian cancer is generally platinum-based therapy, while the high expression of HDAC family members increases the resistance of patients to platinum chemotherapy. Here, HDAC9 is linked to cancer.